Bayer fell short on revenue

Bayer fell short on revenue

A disappointing Q2 for Bayer

One of the world's most recognized pharmaceutical companies, the German conglomerate Bayer, posted its quarterly earnings, and the figures came in lower-than-expected.

Bayer posted earnings per share of €2.67, and revenue of €10.05 billion, underperforming analysts' expectations. The consensus forecasted €10.57 billion worth of revenue and an EPS of €1.5.

Its quarterly sales dropped from a previous €13 billion to €11 billion.

Revenues from the Pharmaceutical segment slipped 8.8% to €3.992 million, as some treatments got postponed due to the pandemic. Among the most affected are ophthalmic and radiological products.

Bayer offered further guidance. It expects that the growth in sales will reach a high of €44 billion, from a previous top of €45 billion. Also, the EPS is seen at a high of €6.90, downgraded from a prior high of €7.20.

Since the beginning of the year, Bayer stocks dropped by 21%, while Germany30 lost 4.89%.

CAPEX.com brings you the latest financial news!

Sources: finance.yahoo.com, investing.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.